Pharmedic Pharmaceutical Medicinal JSC

Pharmedic maintains a strong capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a fully equity-funded balance sheet. The company's liquidity position is reflected in a current ratio of 4.91, suggesting ample short-term assets to cover liabilities. However, operating cash flow is negative at -1,368,625,720 VND, and free cash flow is also negative at -16,943,495,260 VND, indicating that the company is currently not generating sufficient cash from operations to fund its activities.

Profitability metrics show a return on equity (ROE) of 7.58% and a return on assets (ROA) of 6.2%, both of which are positive but should be compared to industry benchmarks to assess relative performance. The company's gross profit margin is 36.56% (50,145,329,810 VND / 137,174,201,350 VND), and its operating margin is 22.10% (30,319,878,310 VND / 137,174,201,350 VND), suggesting a healthy level of profitability relative to its revenue.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue is concentrated in a single business line, as it operates solely in the pharmaceuticals industry. This lack of diversification may increase exposure to sector-specific risks, such as regulatory changes or shifts in demand for pharmaceutical products.

The company's growth trajectory is not clearly defined in the available data, but its current revenue of 137,174,201,350 VND provides a baseline for future performance. The absence of capital expenditures and the negative free cash flow suggest that the company may be in a maintenance or consolidation phase rather than an expansion phase.

Risk factors are minimal, with no immediate liquidity or dilution flags detected. The company's low dilution risk is supported by the fact that basic and diluted shares outstanding are equal, indicating no near-term dilution pressure. However, the negative operating and free cash flows may signal underlying operational inefficiencies or investment in long-term projects that have not yet yielded returns.

Recent events, including filings and transcripts, are not detailed in the available data, but the company's financial snapshot suggests a stable but non-expanding business model. The absence of long-term debt and the strong equity position provide a buffer against short-term financial shocks, but the company may need to address its cash flow challenges to support long-term growth.

Revenue grew at a 7.2% CAGR over four years, demonstrating consistent top-line expansion.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile for financial leverage.

Cash conversion ratio of -0.06 places the company in the bottom quartile of its peer cohort.

Net income growth slowed to just 2.7% year-over-year, lagging behind the 9.7% revenue growth rate.

Operating income growth decelerated to 1.4% year-over-year, signaling weakening operational efficiency gains.

Free cash flow has been negative for three consecutive periods, raising concerns about capital generation.